In a strategic move to realign its business structure, Solara Active Pharma Sciences Limited has incorporated a new wholly owned subsidiary—Synthix Global Pharma Solutions Limited—on April 29, 2025. The incorporation of this entity is directly tied to Solara’s plans to demerge its CRAMS (Contract Research and Manufacturing Services) and Polymers business into an independent entity, aiming for greater operational focus and market adaptability.

Corporate Structure and Capital Details

The newly incorporated company, Synthix Global Pharma Solutions Limited, has been registered with:

• Authorised Capital: ₹15,00,000

• Paid-Up Capital: ₹1,00,000

• Shareholding Pattern: 100% subscribed by Solara Active Pharma Sciences Limited and its nominee shareholders, making Synthix a wholly owned subsidiary.

All shares have been acquired via cash consideration, and the transaction structure makes it a related party transaction, as is common with internal reorganizations.

Business Focus of Synthix Global Pharma

While Synthix Global Pharma is yet to commence operations, the company has been set up within the pharmaceutical industry, with a specific focus on Active Pharmaceutical Ingredients (API). It will play a vital role in Solara’s forward-looking strategy of separating high-growth verticals to allow for independent scaling and strategic investments.

This move is in line with Solara’s strategic objective to unlock value in its different business segments and present a clearer focus to investors and stakeholders.

Strategic Reasoning Behind the Acquisition

The core rationale behind this incorporation stems from Solara’s intent to:

• Streamline operations by isolating the CRAMS and Polymers business.

• Enable independent governance and business development for high-potential segments.

• Improve capital allocation strategies for each business vertical.

This restructuring is not just a technical formality, but a deliberate strategic step to enhance growth prospects and operational flexibility.

Noteworthy Points on Compliance and Interests

• No governmental or regulatory approvals were required for this internal corporate step.

• Other than the related party nature (due to being a wholly owned subsidiary), no promoter group members or group companies have any additional interest in the newly incorporated entity.

• The transaction is conducted at arm's length, aligning with corporate governance standards.

Operational Timeline and Transaction Structure

As per the information provided:

• There is no fixed time frame announced for the completion of the acquisition process since it is an incorporation.

• All shares have been subscribed to through a cash consideration.

• Synthix was incorporated on April 29, 2025, and will begin operations as part of the phased demerger.

Role of Synthix in the Broader Pharmaceutical Ecosystem

Synthix Global Pharma is expected to contribute to India’s growing CRAMS segment, which is gaining international traction. CRAMS, along with Polymers, represents specialized and scalable operations, and separating them into a dedicated subsidiary will:

• Provide operational autonomy.

• Improve investor transparency.

• Allow focused capital infusion and partnerships.

Moreover, given the current market dynamics in APIs and CRAMS, having a dedicated entity with a laser-sharp business focus could significantly improve business outcomes for Solara in the medium to long term.

Conclusion

The incorporation of Synthix Global Pharma Solutions Limited is a major strategic step by Solara Active Pharma Sciences to unlock potential across its diverse pharmaceutical verticals. By segregating the CRAMS and Polymers segments into a wholly owned subsidiary, Solara is making a bold and calculated move to enhance shareholder value, ensure operational efficiency, and capture new market opportunities. The pharmaceutical landscape is evolving rapidly, and this kind of business restructuring is reflective of a forward-thinking corporate strategy.

This move is worth tracking for investors, analysts, and stakeholders interested in India's pharma sector, corporate restructuring trends, and future CRAMS market developments.

The Upcoming IPOs in this week and coming weeks are  Wagons Learning, Srigee DLM, Manoj Jewellers.

The Current active IPO are Kenrik Industries,Arunaya Organics, Ather Energy, Iware Supplychain Services.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.